THURSDAY, 14 JUNE 2018

Can imaging improve diagnosis and outcome in rheumatic diseases

OP0149

AN MRI GUIDED TREAT-TO-TARGET STRATEGY IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION IMPROVED MRI INFLAMMATION BUT NOT DAMAGE PROGRESSION – RESULTS FROM THE IMAGINE-RA RANDOMISED CONTROLLED TRIAL

S. Møller-Bisgaard, K. Hørslev-Pedersen, B. Ejbjerg, D. Glinatsi, M. Hetland, L. Ørnbjerg, J. Møller, M. Boesen, R. Christensen, K. Stengaard-Pedersen, O. R. Madsen, B. Jensen, J. Villadsen, E.-M. Hauge, P. Bennett, O. Hendricks, K. Asmussen, M. Kowalski, H. Lindegaard, S.M. Nielsen, H. Bliddal, N. Krogh, T. Ellingsen, A.H. Nielsen, L. Balding, A.G. Jurik, H. Thomsen, M. Østergaard. *Depts of Rheumatology and Radiology, Musculoskeletal Statistics Unit, Hospitals at Slagelse, Graasten, Gentofte, Aarhus, Frederiksberg, Silkeborg, Hjørring, Odense, Herlev, the Parker Institute and Rigshospitalet, Zealand, Funen and Jutland, Denmark*

Background: Magnetic Resonance Imaging (MRI) bone marrow oedema (BME)/osteitis and MRI synovitis have been identified as predictors of structural damage progression in rheumatoid arthritis RA.^{1,2} Targeting MRI remission may reduce inflammation and halt damage progression.

Objectives: To investigate whether a 2 year treat-to-target (T2T) strategy targeting MRI remission (defined as absence of BME) suppresses MRI-determined measures of disease activity and structural joint damage in RA patients in clinical remission.

Methods: In the two year investigator initiated, randomised, open label multi-centre IMAGINE-RA study, 200 RA patients in clinical remission (defined as DAS28-CRP<3.2 and no swollen joints) receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) were randomised 1:1 to a conventional DAS28-CRP guided T2T treatment strategy targeting DAS28 <3.2 and no swollen joints or an MRI guided T2T treatment strategy applying the same clinical T2T strategy and in addition targeting absence of MRI BME. Patients were followed every 4 months over a 2 year follow-up period. In all patients contrast-enhanced MRIs of the 2nd–5th metacarpophalangeal (MCP) joints and wrist of the dominant hand were performed at baseline, 12 and 24 months. In the MRI T2T arm MRI was performed every 4 months ahead of the clinical visit and assessed for presence/absence of BME by one blinded evaluator so the result was available for the investigator at the visit. In the conventional T2T arm MRI findings were blinded to the investigator. If treatment target was not met treatment was escalated according to a predefined treatment algorithm starting with increment in csDMARD and then adding biologic DMARDs. MRIs (0, 12 and 24 months) were evaluated according to the RAMRIS scoring system, with known chronology by one blinded experienced reader. Pearson's chi-square statistics and repeated-measures logistic regression models were used to assess outcomes.

Results: MRI outcomes of inflammation and damage at 24 months are presented in the table 1. The MRI T2T arm showed statistically significant reductions at 24 months in all inflammatory endpoints (osteitis, tenosynovitis and total inflammation score, $p<0.018$), except synovitis, ($p=0.074$), compared to the conventional T2T arm. No differences between treatment strategies were seen in damage progression.

Abstract OP0149 – Table 1 MRI outcomes at 24 months

MRI outcomes at 24 months				
	MRI T2T	Conventional T2T	Difference between groups (95% CI)	P value*
MRI				
Inflammation				
Change in osteitis (RAMRIS) score	-1.8 (0.6)	-0.1 (0.5)	-1.8 (-3.2 to -0.3)	0.018
Change in synovitis (RAMRIS) score	-0.5 (0.3)	0.3 (0.3)	-0.8 (-1.8 to 0.1)	0.074
Change in tenosynovitis (RAMRIS) score	-0.9 (0.3)	0.3 (0.3)	-1.2 (-2.1 to -0.3)	0.007
Change in total inflammation (RAMRIS) score	-2.9 (1.0)	0.7 (1.0)	-3.6 (-6.4 to -0.8)	0.013
Damage				
Change in erosion (RAMRIS) score	0.5 (0.2)	0.6 (0.2)	-0.1 (-0.6 to 0.4)	0.663
Change in JSN (RAMRIS) score	0.1 (0.2)	0.4 (0.1)	-0.3 (-0.7 to 0.2)	0.236
Change in total damage (RAMRIS) score	0.6 (0.3)	1.0 (0.3)	-0.3 (-1.2 to 0.5)	0.395
No progression in erosion (RAMRIS), n (%)	59 (79.7%)	70 (75.3%)	OR, 1.06 (0.02 to 66.59)	0.976

95% CI, 95% confidence interval; JSN=joint space narrowing; MRI=Magnetic Resonance Imaging; RAMRIS=RA magnetic resonance imaging scoring system; T2T=treat-to-target; total damage score=sum score of MRI erosion and JSN; total inflammation score=sum score of MRI synovitis, osteitis and tenosynovitis. Data are presented as least square means (SE) unless otherwise stated. Analyses are based on full analysis set (patients having a baseline visit and at least one follow-up visit) with no data imputation to replace missing data. *P values are based on repeated-measures logistic regression models. For some of the variables, fewer patients were included in the analyses due to missing data, with the minimum being 85 (range 85-89) in the MRI T2T arm and 90 (range 90-95) in the conventional T2T arm.

Conclusions: An MRI T2T strategy, aiming to eliminate MRI BME, was more effective than a conventional T2T strategy in reducing MRI inflammation but not MRI damage progression. The reduced inflammatory load caused by the MRI T2T strategy may reduce long-term structural joint damage and improve patient-

reported outcomes, but more than two years follow-up data are needed to clarify this.

Clinicaltrials.gov Identifier: NCT01656278

REFERENCE:

- [1] Hetland, et al. Ann Rheum Dis 2009;68(3).
- [2] Boyesen, et al. Ann Rheum Dis 2011;70(3).

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3074

OP0150

ULTRASOUND POWER DOPPLER ACTIVITY PREDICTS CLINICAL JOINT SWELLING IN EARLY RHEUMATOID ARTHRITIS PATIENTS: SECONDARY ANALYSES FROM THE ARCTIC TRIAL

L.B Nordberg^{1,2}, S. Lillegraven², A.-B. Aga², J. Sexton², E. Lie², H.B. Hammer², I. C. Olsen^{2,3}, T. Uhlig², D. van der Heijde^{2,4}, T.K. Kvien², E.A. Haavardsholm^{1,2}.
¹University of Oslo; ²Departement of Rheumatology, Diakonhjemmet Hospital; ³Research Support Services CTU, Oslo, Norway, Oslo University hospital, Oslo, Norway; ⁴Leiden University Medical Center, Leiden, Netherlands

Background: Ultrasound is increasingly applied in the management of rheumatoid arthritis (RA). It is important to detect synovitis early to prevent future joint damage and disability. It is not known whether subclinical ultrasound inflammation in a joint precedes clinical joint swelling.

Objectives: We aimed to investigate whether ultrasound power Doppler (PD) activity in a joint is associated with subsequent clinical joint swelling in early RA patients.

Methods: In the treat-to-target ARCTIC trial, DMARD naïve early RA patients were randomised to follow-up with or without ultrasound, with the same treatment algorithm applied in both arms. Patients were assessed by 44 swollen joint count at all visits (13 visits over two years). Ultrasound examinations were performed using a validated 0–3 semi-quantitative scoring system.¹ with assessments at all visits in the ultrasound arm and at baseline, 12 and 24 months in the conventional arm. We calculated the risk of next-visit clinical joint swelling according to ultrasound inflammation status in clinically non-swollen joints at the preceding visit. We estimated the odds ratio of a joint being swollen at next visit in joints with different PD activity (PD score: 1, 2 or 3), compared to non-swollen joints with no PD activity (PD score=0). These calculations were performed in a logistic mixed-effects model with random intercepts for patient and joint in order to account for within-patient and -joint dependencies, and were adjusted for age, gender, ACPA status, DMARD treatment and strategy arm. Joints injected with corticosteroids were excluded. Data from the two strategy arms were pooled and analysed together, as clinical and radiographic outcomes were similar in the two arms after two years.²

Results: 230 patients were included (118 in the ultrasound strategy arm, 112 in the conventional strategy arm). Mean (SD) age was 51.4 (13.7) years, 61% were female and mean baseline DAS was 3.46 (1.17). The risk of clinical joint swelling at the next visit increased with grade of PD activity (table 1).

Abstract OP0150 – Table 1. Risk of swollen joint at the next visit in joints with subclinical synovitis

Ultrasound assessment	Joint swelling at the next visit n (%)	OR	p-value
PD 0	706/42819 (1.7%)	Reference:	
PD 1	37/469 (7.9%)	3.6 [2.3–5.5]	<0.001
PD 2	33/189 (17.5%)	11.8 [6.9–20.1]	<0.001
PD 3	7/45 (15.6%)	12.1 [4.1–35.7]	<0.001

PD=Power Doppler. Odds ratios are adjusted for within-patient and within-joint dependencies, gender, age, DMARD treatment, ACPA status and strategy arm.

Conclusions: We found PD activity in non-swollen joints to be strongly associated with development of clinical joint swelling at the next visit, and the risk increased with higher power Doppler activity. This study supports the use of ultrasound as a tool to detect joints at risk for developing clinical synovitis.

REFERENCES:

- [1] Hammer HB, et al. ARD 2011.
- [2] Haavardsholm EA, et al. BMJ 2016.

Disclosure of Interest: L. Nordberg: None declared, S. Lillegraven: None declared, A.-B. Aga: None declared, J. Sexton: None declared, E. Lie: None

declared, H. Hammer: None declared, I. Olsen: None declared, T. Uhlig: None declared, D. van der Heijde: None declared, T. Kvien: None declared, E. Haavardsholm Grant/research support from: Pfizer, UCB, Roche, MSD, and AbbVie
DOI: 10.1136/annrheumdis-2018-eular.5318

OP0151
ROUTINELY RECORDED MUSCULOSKELETAL ULTRASOUND FINDINGS IMPACT CLINICIANS' DIAGNOSTIC BEHAVIOUR MAXIMALLY IN AUTOANTIBODY-SERONEGATIVE PATIENTS ATTENDING AN EARLY ARTHRITIS CLINIC

K. Iqbal^{1,2}, D.W. Lendrem^{1,2}, B. Hargreaves^{1,2}, B. Thompson³, J.D. Isaacs^{1,2}, A. G. Pratt^{1,2}. ¹National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University; ²Institute of Cellular Medicine, Newcastle University; ³Musculoskeletal Directorate, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

Background: Musculoskeletal ultrasound (MSUS) is a popular assessment tool, but its contribution to diagnostic practice over and above standard clinical and laboratory parameters has proved difficult to quantify.

Objectives: A published 7-joint ultrasound algorithm¹ has been adapted for pragmatic application during 15 min screening appointments forming part of initial patient assessments in the Newcastle Early Arthritis Clinic (NEAC). Its additive contribution to diagnostic classification in this routine setting was appraised.

Methods: Detailed baseline clinical and laboratory parameters were recorded. Semi-quantitative MSUS scoring (0–3, grey scale and power Doppler) of the most symptomatic wrist (midline and ulnar dorsal longitudinal views), 2nd/3rd MCPs and PIPs and 2nd/5th MTPs (all longitudinal views) was recorded by sonographers, along with the 'sonographer's scan impression' ('definitely inflammatory,' 'possibly inflammatory' or 'non-inflammatory'). All MSUS findings were available to rheumatologist diagnosticians during subsequent consultations, and persistent inflammatory arthritis (PIA) was classified only where patients were started on ≥ 1 disease modifying anti-rheumatic drug (DMARD). Stepwise multiple logistic regression was employed to identify clinical variables that independently predicted IA diagnosis; the additive contribution of MSUS parameters to resultant models was assessed by comparing areas under receiver operator characteristic curves (AU ROCs).

Abstract OP0151 – Figure 1 ROC curves depicting additive discriminatory utility of MSUS 'scan impression' with clinical parameters alone (red), with respect to PIA diagnosis amongst seronegative early arthritis patients. Δ AU AOC=0.08; $p<0.001$

Results: 847 patients were enrolled (17% seropositive for anti-citrullinated peptide autoantibody, ACPA); final outcomes of PIA were recorded in 29% and 18% of the overall and ACPA-seronegative cohorts, respectively. SJC, CRP, age and ACPA status were non-redundant clinical/laboratory predictors of a PIA diagnosis by consulting rheumatologists in the overall cohort (AU ROC 0.85; 95% CI: 0.81 to 0.88), their discriminatory utility being diminished in the seronegative sub-cohort (AU ROC 0.78; 95% CI: 0.72 to 0.82). Although the additive contribution of

summed parameters from the 7-joint MSUS algorithm to the model was statistically significant ($p<0.001$) it was numerically small (Δ AU ROC 0.03 and 0.05 in the overall and seronegative cohorts, respectively). The 'sonographer's scan impression' was a potentially more useful diagnostic tool, its additive contribution to diagnostic outcome over clinical parameters alone being most evident in ACPA-negative patients where it increased the AU ROC by 10% (Δ AU ROC 0.08; $p<0.001$; figure 1).

Conclusions: In this large, un-blinded observational study, the clinical utility of a 15 min MSUS screen for diagnosing PIA requiring DMARDs was particularly evident amongst ACPA negative patients attending an EA clinic.

REFERENCE:

[1] Backhaus, et al. *Arthritis Rheumatol* 61:1194–201.

Acknowledgements: National Institute for Health Research Newcastle Biomedical Research Centre

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.3893

OP0152
IS SONOGRAPHIC PHENOTYPE OF LATE-ONSET RHEUMATOID ARTHRITIS DIFFERENT FROM YOUNG-ONSET RHEUMATOID ARTHRITIS? RESULTS FROM THE BIRMINGHAM EARLY ARTHRITIS COHORT

R. Singh^{1,2}, I. Sahbudin^{1,2}, M. Maybury¹, K. Raza^{1,3}, A. Filer^{1,2}. ¹Rheumatology Research Group, Institute of Inflammation and Ageing, University Hospitals of Birmingham; ²Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham; ³Department of Rheumatology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK

Background: The incidence of rheumatoid arthritis (RA) is generally seen as a bimodal age distribution, which consists of young-onset RA (YORA) and late-onset RA (LORA). Although a retrospective study has reported some differences in sonographic changes between LORA and YORA, little is known whether there are any differences in the clinical and sonographic phenotypes between these two groups during the early disease phases.

Objectives: To compare the clinical and sonographic characteristics between YORA and LORA during the early phases of disease.

Methods: DMARD-naïve patients with clinically apparent synovitis of at least one joint and symptom duration of three months or less were included in the analysis. Patients underwent clinical, ultrasonography and radiological assessments at baseline and final outcomes were determined at 18 months; patients were classified as having RA (according to either the 1987 ACR and/or 2010 ACR/EULAR criteria), a non-RA persistent arthritis or a resolving arthritis. Sonographic assessment included MCP, PIP, wrist, MTP, knee, ankle, elbow joints and wrist, hand flexor, bicep tendon, anteromedial-lateral tendon compartments. The presence and absence of joint synovitis and tenosynovitis were recorded according to the EULAR/OMERACT consensus definition.

	Young-onset RA (n=37)	Late-onset RA (n=36)	Non-RA persistent arthritis (n=27)	Resolving arthritis (n=50)	P (YORA vs LORA)
Age (years)	50 (45–56)	67 (63–73)	39 (31–60)	46 (35–59)	<0.001
EMS (mins)	75 (30–120)	120 (60–240)	60 (10–180)	30 (0–68)	0.808
DAS-28 CRP	5.02 (3.60–5.73)	5.11 (4.49–6.10)	3.77 (3.02–4.95)	3.35 (2.98–4.43)	1.00
RF%					
High	15 (40.5)	10 (27.8)	1 (3.7)	2 (4)	0.568
Positive					
Low	5 (13.5)	7 (19.4)	4 (14.8)	1 (2)	
Positive					
Negative	17 (45.9)	19 (52.8)	22 (81.5)	47 (94)	
ACPA %					0.722
High	17 (45.9)	14 (38.9)	2 (7.4)	2 (4)	
positive					
Low	1 (2.7)	2 (5.6)	0 (0.0)	0 (0.0)	
positive					
Negative	19 (51.4)	20 (55.6)	25 (92.6)	48 (96.0)	
Symptom duration (weeks)	8 (4–10)	8 (6–10)	6 (4–8)	5 (4–8)	1.00
Bilateral MTP squeeze, n (%)	22 (59.5)	10 (27.8)	4 (14.8)	10 (20.0)	0.09

Results: 150 patients were included in the analysis. At 18 months, 37 patients developed YORA, 36 developed LORA, 27 developed non-RA inflammatory arthritis and 50 patients had resolving arthritis. The clinical characteristics